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A serine proteinase with thrombin-like activity was isolated from the venom of the Central American pit viper Bothrops asper.
Isolation was performed by a combination of affinity chromatography on aminobenzamidine-Sepharose and ion-exchange
chromatography on DEAE-Sepharose. The enzyme accounts for approximately 0.13% of the venom dry weight and has a
molecular mass of 32 kDa as determined by SDS-PAGE, and of 27 kDa as determined by MALDI-TOF mass spectrometry. Its
partial amino acid sequence shows high identity with snake venom serine proteinases and a complete identity with a cDNA clone
previously sequenced from this species. The N-terminal sequence of the enzyme is VIGGDECNINEHRSLVVLFXSSGFL
CAGTLVQDEWVLTAANCDSKNFQ. The enzyme induces clotting of plasma (minimum coagulant dose = 4.1 µg) and fibrinogen
(minimum coagulant dose = 4.2 µg) in vitro, and promotes defibrin(ogen)ation in vivo (minimum defibrin(ogen)ating dose = 1.0
µg). In addition, when injected intravenously in mice at doses of 5 and 10 µg, it induces a series of behavioral changes, i.e., loss
of the righting reflex, opisthotonus, and intermittent rotations over the long axis of the body, which closely resemble the ‘gyroxin-
like’ effect induced by other thrombin-like enzymes from snake venoms.
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Viperid snakes of the genus Bothrops sp inflict the vast
majority of snakebites in Central and South America (1,2).
In Central America and parts of northern South America,
the species Bothrops asper is responsible for the majority
of cases (2). Envenomation by this species is associated
with prominent local pathological effects, i.e., myonecro-
sis, hemorrhage, edema, dermonecrosis and blistering
(3), as well as with systemic alterations characterized by
coagulopathy, hemorrhage, cardiovascular shock, and
acute renal failure (2,4,5). Alterations in hemostasis lead-
ing to thrombocytopenia, platelet hypoaggregation,
defibrin(ogen)ation and disseminated intravascular co-
agulation are often observed in victims of B. asper bite
envenomation (5-7). Such complex hemostatic distur-
bances potentiate the profuse bleeding initiated by the
disruptive action of hemorrhagic metalloproteinases in the
microvasculature (7,8).
Viperid venom-induced defibrin(ogen)ation is the conse-
quence of the action of venom procoagulant components on
the clotting system in vivo, since they cause the formation of
microthrombi in the circulation, with the concomitant con-
sumption of fibrinogen and the activation of the fibrinolytic
system, which results in the appearance of fibrin(ogen)-
degradation products (9). These effects result in alteration of
Brazilian Journal of Medical and Biological Research (2008) 41: 12-17
ISSN 0100-879X Short Communication
13
Braz J Med Biol Res 41(1) 2008www.bjournal.com.br
Serine proteinase from Bothrops asper venom
laboratory clotting test parameters, such as whole blood
clotting time, prothrombin time and activated partial throm-
boplastin time (6,9). Procoagulant components in Bothrops
sp venoms include zinc-dependent metalloproteinases that
activate factor X and prothrombin, as well as serine protein-
ases that directly convert fibrinogen into fibrin (10,11). In the
case of B. asper, previous investigations have described a
prothrombin activator, which is a class P-III metalloprotein-
ase named basparin A (12), and a thrombin-like serine
proteinase, named asperase (13,14); however, the charac-
terization of the latter is limited to molecular mass estimation
and amino acid composition, with no sequence information
available. On the other hand, this venom is devoid of factor
X activators (15). Owing to the pathophysiological relevance
of coagulant enzymes in this medically relevant snake venom,
in the present paper we describe the isolation of a thrombin-
like serine proteinase, the determination of its partial amino
acid sequence, and the characterization of its in vitro coagu-
lant and in vivo defibrin(ogen)ating activities.
Serine proteinase was purified by a two-step chromato-
graphic protocol. Samples of 250 mg B. asper venom,
obtained from adult specimens collected in the Pacific re-
gion of Costa Rica, were dissolved in 5 mL 50 mM Tris-HCl,
0.4 M NaCl, pH 9.0. After centrifugation at 500 g for 10 min,
the supernatant was applied to a benzamidine-Sepharose 4
Fast Flow affinity chromatography column (3 x 12 cm; Amer-
sham Biosciences, Uppsala, Sweden), previously equili-
brated with the same buffer. The sample was passed sev-
eral times through the column in order to maximize binding.
After elution of the unbound fraction, a 0.1 M glycine-HCl, pH
3.0, buffer was applied to the column and the absorbance of
the eluting material was monitored at 280 nm. Fractions of 3
mL were collected into tubes containing 0.5 mL 0.5 M Tris
buffer, pH 8.8. Throughout fractionation, fibrinogen-clotting
activity was assessed in order to identify fractions with
thrombin-like activity. To this end, 200 µL of a 4 mg/mL
bovine fibrinogen (Sigma-Aldrich, St. Louis, MO, USA) in
0.12 M NaCl, 40 mM phosphate, pH 7.2 (PBS) was incu-
bated with 100 µL dilutions of the fractions. Proteins from the
peaks showing fibrinogen-clotting activity were diafiltered
and concentrated by ultrafiltration against 50 mM Tris-HCl,
50 mM KCl buffer, pH 9.0. The concentrated material was
applied to a 3 x 8 cm DEAE-Sepharose column previously
equilibrated with the dialysis buffer. After elution of the
unbound material, a linear KCl gradient (50 mM to 0.75 M) in
the same Tris buffer was developed in a total volume of 500
mL. Active peaks were diafiltered against distilled water and
lyophilized. Homogeneity was assessed by reverse-phase
HPLC on a C4 column (Vydac; 250 x 4.6 mm; flow rate 1.0
mL/min) using an Agilent 1100 instrument (Tokyo, Japan)
and a linear gradient from 0 to 60% acetonitrile in 0.1%
trifluoroacetic acid.
For molecular mass analysis and amino acid sequenc-
ing, the fibrinogen-clotting protein purified by DEAE-Sepha-
rose chromatography was submitted to reverse-phase
HPLC using an ETTAN™ LC HPLC system (Amersham
Biosciences, Piscataway, NJ, USA) and a Lichrosphere
RP100 C18 column (250 x 4 mm, 5 µm particle size) eluted
at 1 mL/min with a linear gradient of 0.1% TFA in water
(solution A) and acetonitrile (solution B) employing the
following chromatographic conditions: isocratically (5% B)
for 10 min, followed by linear gradients of 5-15% B over 20
min, 15-45% B over 120 min, and 45-70% B over 20 min.
Protein detection was at 215 nm. Fractions were collected
manually and dried in a Speed-Vac instrument (Savant,
Ramsey, MN, USA). The molecular mass of the purified
protein was determined by SDS-PAGE (16), run under
reducing conditions on 12% polyacrylamide gels and by
MALDI-TOF mass spectrometry (using a Voyager DE-
Pro™ instrument, Applied Biosystem, Foster City, CA, USA,
and sinapinic acid as the matrix) and electrospray ioniza-
tion mass spectrometry using an Applied Biosystem Qtrap™
mass spectrometer (17) operated in Enhanced Multiple
Charge mode in a 600-1700-m/z range.
The purified protein was subjected to N-terminal se-
quence analysis using a Procise instrument (Applied Bio-
systems) following manufacturer instructions. For internal
sequence determination, the protein band of ~30 kDa was
excised from a Coomassie brilliant blue-stained SDS-PAGE
and subjected to automated reduction with DTT and alky-
lation with iodoacetamide, and in-gel digestion with se-
quencing grade bovine pancreas trypsin (Roche, San
Cugart del Vallés, Barcelona, Spain) using a ProGest
digestor (Genomic Solutions, Cambridgeshire, UK) follow-
ing manufacturer instructions. A 0.65-µL amount of the
tryptic peptide mixtures (total volume of ~20 µL) was
spotted onto a MALDI-TOF sample holder, mixed with an
equal volume of a saturated solution of α-cyano-4-hy-
droxycinnamic acid (Sigma) in 50% acetonitrile containing
0.1% TFA, dried, and analyzed with a Voyager-DE Pro
MALDI-TOF mass spectrometer (Applied Biosystems) op-
erated in delayed extraction and reflector modes. A tryptic
peptide mixture of Cratylia floribunda seed lectin (SwissProt
accession code P81517) prepared and previously charac-
terized in our laboratory was used as mass calibration
standard (mass range, 450-3300 Da).
For peptide sequencing, the protein digest mixture was
loaded onto a nanospray capillary column and subjected
to electrospray ionization tandem mass spectrometric anal-
ysis using a QTrap mass spectrometer (Applied Biosys-
tems) (17) equipped with a nanospray source (Protana,
Odense, Denmark). Doubly- or triply-charged ions of se-
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lected peptides from the MALDI-TOF mass fingerprint
spectra were analyzed in Enhanced Resolution MS mode
and the monoisotopic ions were fragmented using the
Enhanced Product Ion tool with Q0 trapping. Enhanced
Resolution was performed at 250 amu/s across the entire
mass range. Settings for MS/MS experiments were as
follows: Q1 - unit resolution; Q1 to Q2 collision energy, 30-
40 eV; Q3 entry barrier, 8 V; linear ion trap Q3 fill time, 250
ms, and Q3 scan rate, 1000 amu/s. Collision-induced
dissociation spectra were interpreted manually or using
the on-line form of the MASCOT program at http://www.
matrixscience. com.
The coagulant activity of fractions and purified enzyme
was assessed on citrated human plasma and on a 4 mg/mL
solution of bovine fibrinogen, dissolved in PBS, as described
above. Samples of 100 µL fractions or various concentra-
tions of the enzyme were added to 200 µL plasma or
fibrinogen, previously incubated at 37°C. Clotting times were
recorded, and the minimum coagulant doses (MCD) for
plasma or fibrinogen were determined; MCD corresponds to
the amount of enzyme that induces clotting in 60 s (18). In
vivo alterations were assessed by intravenous (iv) injection
of various amounts of the enzyme dissolved in 100 µL PBS,
in a group of four CD-1 mice (18-20 g body weight); controls
received the same volume of PBS under otherwise identical
conditions. One hour after injection, mice were bled under
anesthesia. Blood was placed in dry clean glass tubes and
left at room temperature; the formation of clots was regularly
assessed by tilting the tubes, and clotting time was recorded
(18). In addition, mice injected iv were observed for behav-
ioral changes occurring during the first minutes after injec-
tion. Experiments involving mice were approved by the
Institutional Committee for the Care and Use of Laboratory
Animals (CICUA) of the University of Costa Rica.
Fractionation of B. asper venom by affinity chromatog-
raphy on benzamidine-Sepharose yielded a peak, which
bound to the gel, having fibrinogen-clotting activity (Figure
1A). This fraction was separated into five peaks on a
DEAE-Sepharose column eluted with a linear KCl gradient
(Figure 1B). Only peak 1 showed fibrinogen-clotting activ-
ity. When analyzed by reverse-phase HPLC, this peak had
one main component (Figure 1C). The yield of this enzyme
was low, as only 2 mg was recovered from an initial amount
of 1.5 g venom, thus corresponding to approximately 0.13%
of B. asper venom. The apparent molecular mass of this
thrombin-like enzyme was 32 kDa (non-reduced)/24 kDa
(reduced), as determined by SDS-PAGE (Figure 1C, in-
set). MALDI-TOF mass spectrometry evidenced three
molecular species of molecular masses 27,067, 27,356,
and 27,649 Da (± 27 Da). The mass difference of 290-293
Da may indicate that the purified enzyme is a mixture of
glycoforms differing in their degree of sialylation (mass
increment due to sialylation = 292 Da).
N-terminal sequence analysis (Figure 2) revealed 48
residues with high identity with previously characterized
thrombin-like serine proteinases from viperid snake ven-
oms (19). Moreover, the internal sequences of 14 peptides
resulting from tryptic digestion also showed characteristic
sequences of venom serine proteinases. All the sequences
determined showed 100% identity with a deduced amino
acid sequence of a cDNA clone derived from RNA isolated
from the venom gland of B. asper from Costa Rica
(UniProtKB/TrEMBL entry Q072L6; Figure 2). Therefore,
we may conclude that this sequence corresponds to the
thrombin-like serine proteinase described in this commu-
nication. The cDNA-deduced sequence of B. asper serine
proteinase exhibits a single potential N-glycosylation site
at position 20 of the mature protein. The mass difference
between the cDNA-deduced sequence (isotope-averaged
molecular mass = 25308 Da, assuming that its 12 cys-
teines are involved in the formation of disulfide bonds) and
the MALDI-TOF estimated molecular masses support the
hypothesis that each of the three purified thrombin-like
enzyme glycoforms bears a single di-, mono-, or non-
syalilated, fucosylated complex-type dianntenary glycan
chain (calculated mass increments of 2352.1, 2060.1, and
1768.1 Da, respectively). On the other hand, the similarity
in molecular mass with asperase, a thrombin-like serine
proteinase isolated from this venom by Ortiz and Gubensek
(13), suggests that the enzyme described here is likely to
correspond to asperase.
The MCD of the serine proteinase was 4.1 µg for human
plasma and 4.2 µg for bovine fibrinogen. When the enzyme
was incubated with 20 mM PMSF for 30 min at room temper-
ature before addition to fibrinogen, the clotting activity was
abrogated. The MCD of crude B. asper venom for plasma
and fibrinogen are 0.5 µg and 80 µg, respectively (15).
Taken together, these results clearly indicate that a) B. asper
venom contains other more active procoagulant compo-
nents, which very likely correspond to prothrombin-activat-
ing metalloproteinases (12,15), and b) the amount of throm-
bin-like serine proteinase in B. asper venom, and thus its
contribution to the clotting activity is low, in agreement with
the low yield obtained with our fractionation protocol. There-
fore, serine proteinases play a secondary role in the clotting
activity of B. asper venom. This conclusion is supported by
previous experiments in which metalloproteinases were in-
hibited by the peptidomimetic hydroxamate batimastat. Un-
der these conditions, the MCD of B. asper venom increased
from 0.5 µg (uninhibited venom) to 50 µg (batimastat-inhib-
ited venom) (15). Moreover, inhibition of venom serine pro-
teinases by PMSF had little effect on the coagulant activity of
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Figure 1. Isolation of a thrombin-like serine proteinase from Bothrops asper venom. A, Venom (250 mg) was dissolved in 50 mM Tris-
HCl, 0.4 M NaCl, pH 9.0, and applied to a benzamidine-Sepharose 4 Fast Flow column. After elution of unbound material, a 0.1 M
glycine-HCl buffer, pH 3.0, was applied (arrow) and the eluted material was collected into tubes containing 0.5 M Tris buffer, pH 8.8. B,
The benzamidine-binding fraction isolated in A was further fractionated by ion-exchange chromatography on a DEAE-Sepharose
column, equilibrated with 50 mM Tris-HCl, 50 mM KCl buffer, pH 9.0. After elution of unbound material, a linear gradient (G) of KCl from
50 mM to 0.75 M was developed in the same Tris buffer. Only the first peak collected after the onset of the gradient (discontinuous
arrow) had thrombin-like activity. C, Reverse-phase HPLC analysis of the active peak after DEAE-Sepharose separation, carried out
on a C4 column at a flow rate of 1.0 mL/min, using a linear gradient from 0 to 60% acetonitrile in 0.1% trifluoroacetic acid. The inset
shows an SDS-PAGE of the purified protein run under reducing (R) and non-reducing (NR) conditions. D, MALDI-TOF mass spectrum
of the purified thrombin-like enzyme.
the venom (15). Clearly, therefore, metalloproteinases con-
stitute the most important coagulant components of B. asper
venom.
Upon iv injection in mice, the serine proteinase induced
defibrin(ogen)ation. Blood collected from control mice in-
jected with PBS clotted within 2 min, whereas blood col-
lected from mice injected with 10, 5, 2.5, and 1.25 µg of the
enzyme were unclottable; blood from mice receiving 0.5 µg
showed normal clotting. The minimum defibrin(ogen)ating
dose, i.e., the minimum dose that induced defibrin(ogen)ation
in all mice tested, corresponded to 1.0 µg. Thus, this enzyme
has a potent defibrin(ogen)ating activity. The role of serine
proteinases in defibrin(ogen)ation induced by B. asper  venom
has been previously assessed in experiments in which
venom metalloproteinases were inhibited by batimastat (15).
As in the case of in vitro coagulant activity, inhibition of
metalloproteinases greatly reduced the defibrin(ogen)ating
activity of this venom, further supporting the proposed pre-
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dominant role of metalloproteinases over serine proteinases
in B. asper-induced coagulopathy.
Intravenous administration of doses of 10 and 5 µg of
the serine proteinase induced a series of behavioral
changes in mice within the first 2-3 min after injection.
These were characterized by loss of the righting reflex,
opisthotonus, and intermittent rotations over the long axis
of the body. These effects persisted during approximately
10 min, after which the animals apparently recovered. No
such effect was observed with doses below 5 µg. This
effect is very similar to that described for gyroxin, a throm-
bin-like serine proteinase isolated from Crotalus durissus
terrificus venom (20). Similar observations were made with
thrombin-like serine proteinases from other venoms (20). It
is likely that this ‘gyroxin-like’ effect is typical of thrombin-
like serine proteinases from viperid snake venoms, al-
Figure 2. Alignment of the N-terminal sequence of Bothrops asper serine proteinase determined by automated Edman degradation
(N-terminal), and internal amino acid sequences gathered by collision-induced dissociation tandem mass spectrometry of doubly- and
triply-charged tryptic peptides (the m/z value is indicated at the end of each peptide), with the deduced amino acid sequence of a
cDNA clone derived from RNA isolated from the venom gland of B. asper (highlighted in gray) (UniProtKB/TrEMBL entry Q072L6).
The underlined residues correspond to the signal peptide. There is a 100% identity between the sequenced peptides and the deduced
sequence.
though the underlying mechanism remains unknown.
In conclusion, a thrombin-like serine proteinase, pres-
ent in low concentration, was isolated from the venom of B.
asper from Costa Rica. It is likely that this enzyme corre-
sponds to asperase, isolated from this venom (13,14), and
to a previously described sequence (UniProtKB/TrEMBL
entry Q072L6). The enzyme displays fibrinogen-clotting
activity in vitro and defibrin(ogen)ating activity in vivo, and
is likely to play a role, albeit not a predominant one, in the
coagulopathy characteristic of envenomation inflicted by
B. asper bites.
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